PhRMA v. Thompson
Washington, D.C. appeals court is scheduled to hear oral arguments in the Pharmaceutical Research & Manufacturers of America's case against HHS' approval of the Healthy Maine Prescription demonstration program Dec. 5. The D.C. federal court ruled that the program qualifies for manufacturer rebates (1'The Pink Sheet" March 4, p. 13)...
You may also be interested in...
Maine's Medicaid waiver program qualifies for manufacturer rebates because of the state's contribution to beneficiaries' prescription costs, the D.C. federal court decided Feb. 25
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.